Al-Hazmi Shrouq F, Gad Hoda G M, Alamoudi Aliaa A, Eldakhakhny Basmah M, Binmahfooz Sarah K, Alhozali Amani M
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. E-mail.
Saudi Med J. 2020 Jul;41(7):690-697. doi: 10.15537/smj.2020.7.25168.
To evaluate 2 renal tubular enzymes; urinary neutrophil gelatinase-associated lipocalin (uNGAL), and urinary N-acetyl-beta-D-glucosaminidase (uNAG), and serum Cystatin C as candidate biomarkers for early diagnosis of early stage of diabetic nephropathy (DB) in patients with type 2 diabetes mellitus (T2DM).
This cross-sectional study was carried out at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia during the period between May 2017 and May 2018 and was conducted on 86 patients with T2DM. Patients were classified according to their albumin/creatinine ratio (ACR) into 3 groups; a normal albuminuria group with ACR less than 30 mg/g creatinine, a moderately increased albuminuria group with ACR: 30-299 mg/g creatinine, and a severely increased albuminuria group with ACR ≥300 mg/g. Healthy adults were recruited as a control group. Urine uNGAL, uNAG, and serum Cystatin C were measured in all patients.
Compared with healthy control, diabetic patients with normal albuminuria excreted significantly higher levels of uNGAL (p less than 0.001). In addition, significantly elevated uNGAL, uNAG and cystatin C levels were observed in moderately increased albuminuria and severely increased albuminuria groups when compared to the control and normoalbuminuric groups (p less than 0.001). urinary neutrophil gelatinase-associated lipocalin, urinary N-acetyl-beta-D-glucosaminidase and Cystatin C showed a positive correlation with fasting blood glucose (FBG), HbA1c, duration of diabetes, urea, creatinine, and ACR.
Our results indicated that uNGAL could be a sensitive biomarker for early renal dysfunction in diabetic patients while uNAG and serum Cystatin C might have prognostic value.
评估两种肾小管酶,即尿中性粒细胞明胶酶相关脂质运载蛋白(uNGAL)和尿N - 乙酰 - β - D - 氨基葡萄糖苷酶(uNAG),以及血清胱抑素C作为2型糖尿病(T2DM)患者早期糖尿病肾病(DB)早期诊断的候选生物标志物。
这项横断面研究于2017年5月至2018年5月在沙特阿拉伯吉达的阿卜杜勒阿齐兹国王大学医院(KAUH)进行,研究对象为86例T2DM患者。根据白蛋白/肌酐比值(ACR)将患者分为3组:ACR低于30 mg/g肌酐的正常蛋白尿组、ACR为30 - 299 mg/g肌酐的中度蛋白尿增加组和ACR≥300 mg/g的重度蛋白尿增加组。招募健康成年人作为对照组。对所有患者测量尿uNGAL、uNAG和血清胱抑素C。
与健康对照组相比,正常蛋白尿的糖尿病患者排泄的uNGAL水平显著更高(p小于0.001)。此外,与对照组和正常蛋白尿组相比,中度蛋白尿增加组和重度蛋白尿增加组的uNGAL、uNAG和胱抑素C水平显著升高(p小于0.001)。尿中性粒细胞明胶酶相关脂质运载蛋白、尿N - 乙酰 - β - D - 氨基葡萄糖苷酶和胱抑素C与空腹血糖(FBG)、糖化血红蛋白(HbA1c)、糖尿病病程、尿素、肌酐和ACR呈正相关。
我们的结果表明,uNGAL可能是糖尿病患者早期肾功能障碍的敏感生物标志物,而uNAG和血清胱抑素C可能具有预后价值。